Glycopyrrolate + Formoterol Suppliers & Bulk Manufacturers
Available Forms: Pressurized metered-dose inhaler (pMDI)
Available Strengths: Glycopyrrolate 9 mcg + Formoterol fumarate 4.8 mcg
Reference Brands: Bevespi Aerosphere(US)
Category:
Respiratory Disorder
Glycopyrrolate + Formoterol is a LAMA/LABA combination used for COPD maintenance treatment. Marketed as Bevespi Aerosphere in the U.S., it offers twice-daily bronchodilation via a metered-dose inhaler, helping improve lung function and reduce breathlessness in COPD patients. It is not intended for acute symptom relief.
Glycopyrrolate + Formoterol is available in Pressurized metered-dose inhaler (pMDI)
and strengths such as Glycopyrrolate 9 mcg + Formoterol fumarate 4.8 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Glycopyrrolate + Formoterol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Glycopyrrolate + Formoterol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Glycopyrrolate + Formoterol is a long-acting bronchodilator combination used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate, a LAMA, and Formoterol, a LABA, work together to relax airway muscles, improve airflow, and reduce symptoms like breathlessness. Marketed as Bevespi Aerosphere in the United States, this combination is delivered via a pressurized metered-dose inhaler (pMDI) and taken twice daily. It is not intended for acute symptom relief but provides long-term control of COPD symptoms. Bevespi Aerosphere helps enhance lung function, reduce exacerbations, and improve the overall quality of life for patients with moderate to severe COPD.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing